(December 16, 2020, 1:40 PM EST) -- BOSTON — Several current and former executive officers and directors of a commercial-stage pharmaceutical company breached their fiduciary duty and violated federal securities laws by misrepresenting the safety, efficacy and survival distribution data obtained during clinical trials in seeking regulatory approval of the company’s cancer treatment drug, a trust alleges in a Dec. 14 shareholder derivative complaint filed in Massachusetts federal court (Vladimir Gusinsky Revocable Trust v. Michael G. Kaufman, et al., No. 20-12213, D. Mass.)....